Correction to: Eye (2015) 29, 1633–1638; doi: 10.1038/eye.2015.164; published online 28 August 2015

Since the online publication of this paper, the authors have been made aware of an error (as referenced in the recently published letter by Dr Ting). The authors agree with the letter that TA283 is the relevant NICE Guidance in relation to the use of ranibizumab in the treatment of macular oedema secondary to RVO and not TA238. This was a typographical error that the authors accept and hereby correct.

The authors would like to apologise for this error.

This error has now been rectified, and the corrected article appears in this issue. The html and online pdf versions have also been rectified, and now carry the corrected paper.